Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Transfusion management in the era of magrolimab (Hu5F9‐G4), an anti ...
The anti‐CD47 antibody magrolimab with obinutuzumab and venetoclax in ...
Cathy Eng: The Anti-CD47 Antibody Magrolimab with Cetuximab in Patients ...
Magrolimab | TargetMol
Buy Magrolimab (CD47 ) Antibody, Monoclonal | Axil Scientific
Buy research grade Magrolimab biosimilar ，anti-CD47, Hu5F9-G4 antibody
Guidance for transfusion management in patients receiving magrolimab ...
Magrolimab Biosimilar, Igg1 Biosimilar (CD47) Antibody (HDBS0049)
Magrolimab Biosimilar - Anti-CD47 Antibody (A318907)
Magrolimab (CD47 ) Antibody, Monoclonal - Cat. No.10-950 | ProSci
Magrolimab Biosimilar (Anti-CD47) Antibody (HDBS0001)
Magrolimab (Hu5F9-G4，莫洛利单抗) - 仅供科研 | CD47抗体 | MCE
The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination ...
Efficacy of magrolimab + azacitidine in untreated AML and MDS patients ...
A Phase 1b/2 Study of the Anti-CD47 Antibody Magrolimab with Cetuximab ...
Magrolimab (anti-CD47) Datasheet
Combining the novel anti-CD47 antibody magrolimab with azacitidine in ...
675 Safety and tolerability of magrolimab combination therapy in ...
Magrolimab Therapy in Conjunction with Conventional Chemotherapeutics ...
Magrolimab in Combination With Azacitidine in Patients With Higher-Risk ...
Gilead drops CD47 drug magrolimab for blood cancers | pharmaphorum
Study on the Safety and Effectiveness of Magrolimab with Bevacizumab ...
FDA Places Full Clinical Hold on Magrolimab Trials in AML, MDS ...
CD47 Levels Are Prognostic of Response to Magrolimab Plus Docetaxel in ...
Magrolimab Plus Azacitidine Demonstrates Durable Response in Patients ...
FDA Fast-tracks Magrolimab for Treatment of Myelodysplastic Syndrome ...
FDA slaps hold on trials of Gilead's CD47 drug magrolimab | pharmaphorum
Magrolimab - Multiple Myeloma Clinical Trials
Trial Evaluating Magrolimab Plus Azacitidine in Higher-Risk MDS ...
阻断肿瘤“别吃我”信号！吉利德CD47单抗magrolimab一线治疗急性髓性白血病(AML)：缓解率63% - 癌症研究专区 - 生物谷
Magrolimab: Unveiling the Role of Anti-CD47 in Cancer Research and ...
Forty Seven, Inc. Announces Updated Data from Ongoing Clinical Trial of ...
Structure of the Magrolimab/CD47 complex. The FG and BC loops of CD47 ...
ASH 2022：武田CD47单抗Magrolimab为基础的三联治疗在AML中取得显著突破-MedSci.cn
Frontiers | Therapeutic Targeting of the Macrophage Immune Checkpoint ...
Targeting macrophages with anti-CD47 antibody (magrolimab). | Download ...
再鼎医药首个自主研发抗体新药-CD47单抗获批临床 - 癌症123
Biotinylated Anti-CD47 (magrolimab biosimilar) mAb-CD47 Biosimilar mAb ...
Phase Ib Efficacy Safety of AntiCD 47 Antibody
CD47靶点新药研发：富贵险中求
Anti-CD47 (magrolimab biosimilar;IgG1) mAb-CD47 Biosimilar mAb for ...
Anti-CD47 (magrolimab biosimilar) mAb-CD47 Biosimilar mAb for ELISA ...
S132: TOLERABILITY AND EFFICACY OF THE FIRST-IN-CLASS ANTI-CD47 ...
Anti-CD47 (magrolimab biosimilar) mAb
Gilead’s Magrolimab, an Investigational Anti-CD47 Monoclonal Antibody ...
magrolimab治疗骨髓增生异常综合征获FDA突破性药物资格 - 知乎
Anti-CD47 Therapy and Other New Approaches to the Treatment of ...
Tolerability and efficacy of the first-in-class anti-CD47 antibody ...
Ligufalimab, a novel anti-CD47 antibody with no hemagglutination ...
(PDF) S132: TOLERABILITY AND EFFICACY OF THE FIRST-IN-CLASS ANTI-CD47 ...
美国APExBIO中文官网 - Anti-CD47 Antibody (Magrolimab)
Frontiers | CD47 as a promising therapeutic target in oncology
莫洛利单抗(Magrolimab) - 药物靶点：CD47_在研适应症：弥漫内生性脑桥神经胶质瘤，弥漫性中线胶质瘤，胶质瘤_专利_临床_研发
(Magrolimab)Biosimilar Reference Antibody
吉利德终止CD47单抗治疗骨髓增生异常综合征III期研究 7月21日， 吉利 德宣布，CD47单抗magrolimab联合阿扎胞苷治疗高风险 ...
Pyroglutamation of cell surface proteins CD47 and TRP1 by glutaminyl ...
CD47-targeting antibodies as a novel therapeutic strategy in ...
Magrolimab: Detailed Review of its Transformative R&D Success
莫洛利单抗(Magrolimab) - 药物靶点：CD47_在研适应症：急性髓性白血病，转移性输尿管癌，尿道移行细胞癌_专利_临床_研发
吉利德CD47抗体折戟三期MDS临床，中国Biotech有望后发先至__财经头条
吉利德终止CD47单抗治疗骨髓增生异常综合征III期研究 7月21日，吉利德宣布，CD47单抗magrolimab联合阿扎胞苷治疗高风险骨髓 ...
Effect of CD47 Blockade on Vascular Inflammation - PMC
CD47靶点拓荒之旅，距离真相越来越近_财富号_东方财富网
genO‑hCD47/hSIRPα model - 模型资源 - 基锘威 - genOway
Tolerability and Efficacy of the Anticluster of Differentiation 47 ...
Frontiers | Generation of a potent anti-PD-L1-CD47 bispecific antibody ...
Magrolimab: A new weapon against cancer cells - BJH
全球超20款CD47单抗迈入临床，中国占一半！|CD47|巨噬细胞|红细胞|临床|-健康界
2023年7月 | 失败临床研究TOP8 7月，吉利德CD47单抗magrolimab在首个III期研究中被证明疗效不足，给整个CD47靶点的 ...
吉利德CD47 MDS 3期数据将在下半年揭晓 吉利 德预计，Magrolimab针对骨髓增生异常综合征的3期临床（ENHANCE）期中分析 ...
The Macrophage ‘Do not eat me’ signal, CD47, is a clinically validated ...
Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma - PMC
Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis ...
CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on ...
CD47 Monoclonal Antibody (B6H12.2) | Invitrogen (MA5-11895)
a. Anti-CD47 mAb inhibited tumor growth in an immunocompetent syngeneic ...
I-Mab reports efficacy of Anti-CD47 monoclonal Ab on relapsed ...
CD47 monoclonal antibody (mAb)-treated tumors show increased ...
Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 ...
Maplirpacept: a CD47 decoy receptor with minimal red blood cell binding ...
Preclinical and clinical development of therapeutic antibodies ...
A Monoclonal Antibody Directed Against Human CD47 Enables Phagocytosis ...
Monoclonal antibody specifically binding to human CD47 and application ...
突破！CD47单克隆抗体Lemzoparlimab用于治疗复发或难治性恶性肿瘤初步显示疗效信号 处于业界领先地位 - 公司专区 - 生物谷
.gif)
.jpg)
Biosimilar-Reference-Antibody-GS40417-SDS-PAGE-Mabnus.png)
Biosimilar-Reference-Antibody-GS40417-ELISA-Mabnus.png)
